aspirin has been researched along with Prosthesis Durability in 36 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aspirin for metal stents in malignant distal common bile duct obstruction (AIMS) study should determine the efficacy of aspirin in maintaining metal-stent patency in patients with malignant distal CBD obstructive." | 9.34 | Aspirin for metal stent in malignant distal common bile duct obstruction (AIMS): study protocol for a multicenter randomized controlled trial. ( Choi, JH; Choi, YH; Kim, YT; Lee, KJ; Lee, SH; Paik, WH; Ryu, JK; Shin, BS; You, MS, 2020) |
| " The patient had decided to take low-molecular-weight heparin (LMWH) and aspirin throughout her pregnancy." | 7.74 | Acute thrombosis of a prosthetic mitral valve in pregnancy in spite of adjusted-dose low-molecular-weight heparin and aspirin. ( Curtis, SL; Stuart, AG; Trinder, J, 2008) |
| "The aspirin for metal stents in malignant distal common bile duct obstruction (AIMS) study should determine the efficacy of aspirin in maintaining metal-stent patency in patients with malignant distal CBD obstructive." | 5.34 | Aspirin for metal stent in malignant distal common bile duct obstruction (AIMS): study protocol for a multicenter randomized controlled trial. ( Choi, JH; Choi, YH; Kim, YT; Lee, KJ; Lee, SH; Paik, WH; Ryu, JK; Shin, BS; You, MS, 2020) |
| "Definite/probable ST and MB (TIMI major and Bleeding Academic Research Consortium (BARC) ≥ 3) were compared in 2 subsequent trials with similar inclusion criteria but different DAPT duration, that is, BASKET (6 months; n = 557) and BASKET-PROVE (12 months; n = 2,314), between months 0 to 6 (DAPT in both trials), 7 to 12 (DAPT in BASKET-PROVE only), and 13 to 24 (aspirin in both trials) using propensity score-adjusted, time-stratified Cox proportional hazard models." | 5.19 | Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. ( Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S, 2014) |
| "The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme." | 4.90 | Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014) |
| " The patient had decided to take low-molecular-weight heparin (LMWH) and aspirin throughout her pregnancy." | 3.74 | Acute thrombosis of a prosthetic mitral valve in pregnancy in spite of adjusted-dose low-molecular-weight heparin and aspirin. ( Curtis, SL; Stuart, AG; Trinder, J, 2008) |
| "Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation." | 2.79 | Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014) |
| "Cilostazol has been reported to reduce intimal hyperplasia and subsequent repeat revascularization." | 2.79 | Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial. ( Bae, JH; Baek, JY; Bong, JM; Cho, JH; Cho, YH; Choi, CU; Choi, HJ; Choi, SH; Choi, WG; Chung, WY; Her, SH; Kang, WY; Kim, EJ; Kim, JH; Kim, KC; Kim, MW; Kim, SM; Kim, WH; Kim, YH; Kim, YJ; Lee, SJ; Oh, DJ; Park, MW; Park, SH; Rha, SW; Seo, JB; Soh, JW; Suh, J, 2014) |
| "Aspirin has been shown to be a safe and cost-effective thromboprophylaxis agent with equivalent preventive efficacy to warfarin and fewer side-effects." | 1.51 | Aspirin Thromboprophylaxis Confers No Increased Risk for Aseptic Loosening Following Cementless Primary Hip Arthroplasty. ( Courtney, PM; Goswami, K; Rondon, AJ; Schlitt, PK; Shohat, N; Tan, TL; Yayac, M, 2019) |
| "Warfarin treatment was an independent predictor of both primary endpoint (OR 1." | 1.34 | Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. ( Airaksinen, KE; Airaksinen, TJ; Karjalainen, PP; Niemelä, M; Nyman, K; Porela, P; Vahlberg, T; Vaittinen, MA; Vikman, S; Ylitalo, A, 2007) |
| "Bioprosthetic valve thrombosis is a rare complication, supporting this approach." | 1.31 | Early bioprosthetic mitral valve "pseudostenosis" after complete preservation of the native mitral apparatus. ( Korkolis, DP; Koullias, GJ; Marshalko, SJ; Passik, CS, 2002) |
| "Aspirin and heparin were embedded in chitosan/polyethylene vinylacetate co-matrix to develop a prolonged release form." | 1.31 | Synergistic effect of released aspirin/heparin for preventing bovine pericardial calcification. ( Chandy, T; Mohanty, M; Sharma, CP; Umasankar, PR; Vasudev, SC, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.78) | 18.7374 |
| 1990's | 5 (13.89) | 18.2507 |
| 2000's | 11 (30.56) | 29.6817 |
| 2010's | 16 (44.44) | 24.3611 |
| 2020's | 3 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, JH | 2 |
| Lee, KJ | 2 |
| Paik, WH | 2 |
| Park, N | 1 |
| Chun, JW | 1 |
| Lee, SH | 2 |
| Ryu, JK | 2 |
| Kim, YT | 2 |
| You, MS | 1 |
| Choi, YH | 1 |
| Shin, BS | 1 |
| Varol, S | 1 |
| Şahin, İ | 1 |
| Kum, G | 1 |
| Katkat, F | 1 |
| Okuyan, E | 1 |
| Hage, A | 1 |
| Jacques, F | 1 |
| Chetaille, P | 1 |
| Bourdages, M | 1 |
| Cloutier, K | 1 |
| Perron, J | 1 |
| Houde, C | 1 |
| Goswami, K | 1 |
| Tan, TL | 1 |
| Rondon, AJ | 1 |
| Shohat, N | 1 |
| Yayac, M | 1 |
| Schlitt, PK | 1 |
| Courtney, PM | 1 |
| Park, J | 1 |
| Shin, DH | 1 |
| Kim, BK | 1 |
| Her, AY | 1 |
| Kim, YH | 2 |
| Choi, HH | 1 |
| Kim, JS | 1 |
| Ko, YG | 1 |
| Choi, D | 1 |
| Jang, Y | 1 |
| Hong, MK | 1 |
| Efthymiou, CA | 1 |
| Mills, RJ | 1 |
| O'Regan, DJ | 1 |
| Pergolini, A | 1 |
| Pino, PG | 1 |
| Zampi, G | 1 |
| Polizzi, V | 1 |
| Musumeci, F | 1 |
| Silber, S | 1 |
| Kirtane, AJ | 1 |
| Belardi, JA | 1 |
| Liu, M | 1 |
| Brar, S | 1 |
| Rothman, M | 1 |
| Windecker, S | 2 |
| Camenzind, E | 1 |
| Boersma, E | 1 |
| Wijns, W | 1 |
| Mauri, L | 1 |
| Rademaker-Havinga, T | 1 |
| Ordoubadi, FF | 1 |
| Suttorp, MJ | 1 |
| Al Kurdi, M | 1 |
| Steg, PG | 1 |
| Sousa, C | 1 |
| Almeida, J | 1 |
| Dias, P | 1 |
| Almeida, P | 1 |
| Rangel, I | 1 |
| Araújo, V | 1 |
| Macedo, F | 1 |
| Maciel, MJ | 1 |
| Park, SH | 1 |
| Rha, SW | 1 |
| Choi, CU | 1 |
| Kim, EJ | 1 |
| Oh, DJ | 1 |
| Cho, YH | 1 |
| Choi, WG | 1 |
| Lee, SJ | 1 |
| Choi, SH | 1 |
| Kim, WH | 1 |
| Kim, KC | 1 |
| Cho, JH | 1 |
| Kim, JH | 1 |
| Kim, SM | 1 |
| Bae, JH | 1 |
| Bong, JM | 1 |
| Kang, WY | 1 |
| Baek, JY | 1 |
| Seo, JB | 1 |
| Chung, WY | 1 |
| Park, MW | 1 |
| Her, SH | 1 |
| Suh, J | 1 |
| Kim, MW | 1 |
| Kim, YJ | 1 |
| Choi, HJ | 1 |
| Soh, JW | 1 |
| Jeger, RV | 1 |
| Pfisterer, ME | 1 |
| Sørensen, R | 1 |
| von Felten, S | 1 |
| Alber, H | 1 |
| Bonetti, PO | 1 |
| Eberli, F | 1 |
| Erne, P | 1 |
| Pedrazzini, G | 1 |
| Rickli, H | 1 |
| Galatius, S | 1 |
| Kaiser, CA | 1 |
| Tara, S | 1 |
| Kurobe, H | 1 |
| de Dios Ruiz Rosado, J | 1 |
| Best, CA | 1 |
| Shoji, T | 1 |
| Mahler, N | 1 |
| Yi, T | 1 |
| Lee, YU | 1 |
| Sugiura, T | 1 |
| Hibino, N | 1 |
| Partida-Sanchez, S | 1 |
| Breuer, CK | 1 |
| Shinoka, T | 1 |
| Acibuca, A | 1 |
| Gerede, DM | 1 |
| Vurgun, VK | 1 |
| Ghodsizad, A | 1 |
| Badiye, A | 1 |
| Zeriouh, M | 1 |
| Pae, W | 1 |
| Koerner, MM | 1 |
| Loebe, M | 1 |
| Giannini, C | 1 |
| De Carlo, M | 2 |
| Guarracino, F | 1 |
| Donne, MG | 1 |
| Benedetti, G | 1 |
| Verunelli, F | 1 |
| Petronio, AS | 2 |
| Barison, A | 1 |
| Bellini, F | 1 |
| Capozza, PF | 1 |
| Lunardini, A | 1 |
| Romlin, BS | 1 |
| Wåhlander, H | 1 |
| Strömvall-Larsson, E | 1 |
| Synnergren, M | 1 |
| Baghaei, F | 1 |
| Jeppsson, A | 1 |
| Korkolis, DP | 1 |
| Passik, CS | 1 |
| Marshalko, SJ | 1 |
| Koullias, GJ | 1 |
| Lasry, JL | 1 |
| Borie, H | 1 |
| Coppé, G | 1 |
| Hovasse, D | 1 |
| Pernès, JM | 1 |
| Strecker, EP | 1 |
| Boos, IB | 1 |
| Göttmann, D | 1 |
| Vetter, S | 1 |
| Karvouni, E | 1 |
| Korovesis, S | 1 |
| Katritsis, DG | 1 |
| Aoyagi, S | 1 |
| Arinaga, K | 1 |
| Fukunaga, S | 1 |
| Tayama, E | 1 |
| Kosuga, T | 1 |
| Akashi, H | 1 |
| Wiper, AJ | 1 |
| Roberts, DH | 1 |
| Wenaweser, P | 1 |
| Billinger, M | 1 |
| Cook, S | 1 |
| Togni, M | 1 |
| Meier, B | 1 |
| Haeberli, A | 1 |
| Hess, OM | 1 |
| Karjalainen, PP | 1 |
| Porela, P | 1 |
| Ylitalo, A | 1 |
| Vikman, S | 1 |
| Nyman, K | 1 |
| Vaittinen, MA | 1 |
| Airaksinen, TJ | 1 |
| Niemelä, M | 1 |
| Vahlberg, T | 1 |
| Airaksinen, KE | 1 |
| Jiménez-Quevedo, P | 1 |
| Sabaté, M | 1 |
| Angiolillo, DJ | 1 |
| Alfonso, F | 1 |
| Hernández-Antolín, R | 1 |
| SanMartín, M | 1 |
| Gómez-Hospital, JA | 1 |
| Bañuelos, C | 1 |
| Escaned, J | 1 |
| Moreno, R | 1 |
| Fernández, C | 1 |
| Fernández-Avilés, F | 1 |
| Macaya, C | 1 |
| Curtis, SL | 1 |
| Trinder, J | 1 |
| Stuart, AG | 1 |
| Saad, EM | 1 |
| Kaplan, S | 1 |
| el-Massry, S | 1 |
| Kaplan, A | 1 |
| Marcoe, KF | 1 |
| Zammit, M | 1 |
| Fisher, LD | 1 |
| Sauvage, LR | 1 |
| Burger, W | 1 |
| Kneissl, GD | 1 |
| Hartmann, A | 1 |
| Bauersachs, R | 1 |
| Döring, V | 1 |
| Spengler, U | 1 |
| Neumann, G | 1 |
| Rothe, KW | 1 |
| Oemrawsingh, PV | 1 |
| Schalij, MJ | 1 |
| Udayachalerm, W | 1 |
| van der Wall, EE | 1 |
| Bruschke, AV | 1 |
| Goldsmith, I | 1 |
| Lip, GY | 1 |
| Mukundan, S | 1 |
| Rosin, MD | 1 |
| Vasudev, SC | 1 |
| Chandy, T | 1 |
| Sharma, CP | 1 |
| Mohanty, M | 1 |
| Umasankar, PR | 1 |
| Graham, LM | 1 |
| Brothers, TE | 1 |
| Vincent, CK | 1 |
| Burkel, WE | 1 |
| Stanley, JC | 1 |
| Clyne, CA | 1 |
| Archer, TJ | 1 |
| Atuhaire, LK | 1 |
| Chant, AD | 1 |
| Webster, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Aspirin on Patency of Metal Stent in Malignant Distal Bile Duct Obstruction[NCT03279809] | 52 participants (Actual) | Interventional | 2017-10-12 | Terminated (stopped due to One grade 4 adverse event (AE) and common (47.2%) grade 3 AEs) | |||
| RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128] | 2,349 participants (Actual) | Observational | 2008-08-31 | Completed | |||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453] | 1,516 participants (Actual) | Interventional | 2008-07-31 | Completed | |||
| The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940] | 100 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084] | Phase 4 | 2,292 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957] | Phase 4 | 8,709 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Efficacy of Self-Expanding Nitinol S.M.A.R.T-CONTROL Stent Versus Complete SE Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP Trial)[NCT01570803] | 0 participants (Actual) | Interventional | 2013-01-31 | Withdrawn (stopped due to Study could not be initiated due to lack of research funding from the sponsors.) | |||
| Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study[NCT00738556] | 179 participants (Actual) | Interventional | 2003-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00752128)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Cardiac Death or Target Vessel MI | 4.2 |
(NCT00752128)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Overall Stent Thrombosis (Definite and Probable-ARC) | 0.9 |
(NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 1.3 |
Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 5.5 |
Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 0.1 |
Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 4.7 |
Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 6.3 |
Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of eligible participants (Number) |
|---|---|
| Primary Enrollment Group | 1.4 |
The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months
| Intervention | mm (Mean) |
|---|---|
| Zotarolimus Eluting Stent | 0.13 |
Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months
| Intervention | percentage of participants with TLF (Number) |
|---|---|
| Zotarolims Eluting Stent | 4.0 |
In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months
| Intervention | Percentage diameter stenosis (Mean) |
|---|---|
| 1. Resolute - 12-13 Months | 21.65 |
| 2. XIENCE V - 12-13 Months | 19.76 |
Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| 1. Resolute - 12-13 Months | 8.2 |
| 2. XIENCE V - 12-13 Months | 8.3 |
Definite or probable stent thrombosis rate. (NCT00476957)
Timeframe: 3 years
| Intervention | participants (Number) |
|---|---|
| E-ZES | 61 |
| C-SES | 75 |
Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Total death and large non-fatal myocardial infarct | Total death and non-fatal myocardial infarctions | Cardiac death and large non-fatal MI | Cardiac death and non-fatal MI | Target lesion revascularization | Stroke | Bleeding events | |
| C-SES | 255 | 360 | 174 | 282 | 156 | 72 | 184 |
| E-ZES | 225 | 331 | 157 | 265 | 249 | 77 | 201 |
2 reviews available for aspirin and Prosthesis Durability
| Article | Year |
|---|---|
Early postoperative thrombosis of an aortic bioprosthetic valve: should anticoagulation be patient specific?
Topics: Administration, Oral; Aged; Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Aspirin; Bioprosthe | 2013 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
8 trials available for aspirin and Prosthesis Durability
| Article | Year |
|---|---|
Acetylsalicylic acid for metal stent in malignant distal common bile duct obstruction: A randomized controlled trial.
Topics: Aspirin; Bile Duct Neoplasms; Cholangiopancreatography, Endoscopic Retrograde; Cholestasis; Humans; | 2022 |
Aspirin for metal stent in malignant distal common bile duct obstruction (AIMS): study protocol for a multicenter randomized controlled trial.
Topics: Aspirin; Cholangiopancreatography, Endoscopic Retrograde; Cholestasis; Common Bile Duct; Double-Blin | 2020 |
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
Topics: Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin | 2014 |
Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial.
Topics: Alloys; Angioplasty, Balloon; Aspirin; Cilostazol; Clinical Protocols; Clopidogrel; Drug Therapy, Co | 2014 |
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-El | 2014 |
Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
Topics: Aged; Aspirin; Atorvastatin; Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Comb | 2007 |
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death, | 2007 |
Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Female; Humans; Male; Po | 1987 |
26 other studies available for aspirin and Prosthesis Durability
| Article | Year |
|---|---|
Coronary stent embolism to the right posterior cerebral artery.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atropine; Clopidogrel; Coronary Angiography; Coronary Arter | 2020 |
Thrombolysis of prosthetic mitral valve thrombosis in an infant.
Topics: Aspirin; Coronary Vessels; Female; Fibrinolytic Agents; Heart Septal Defects, Ventricular; Heart Val | 2017 |
Aspirin Thromboprophylaxis Confers No Increased Risk for Aseptic Loosening Following Cementless Primary Hip Arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Hip Prosthesis; Humans; Prosthesis Design; | 2019 |
Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Confidence Intervals; Co | 2013 |
Thrombotic aortic restenosis after transapical SAPIEN valve implantation.
Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Clopidogrel; Echoc | 2014 |
Conservative management of a prosthetic valve thrombosis--report of a successful case.
Topics: Adult; Anticoagulants; Aortic Valve; Aspirin; Fibrinolytic Agents; Heart Valve Prosthesis; Heparin; | 2014 |
Cilostazol, Not Aspirin, Prevents Stenosis of Bioresorbable Vascular Grafts in a Venous Model.
Topics: Absorbable Implants; Animals; Aspirin; Blood Vessel Prosthesis; Cell Proliferation; Cilostazol; Dise | 2015 |
Bare-metal stent thrombosis two decades after stenting.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Electr | 2015 |
Pump Thrombosis following HeartMate II Left Ventricular Assist Device Implantation in a Patient with Aspirin and Plavix Resistance.
Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Heart Failure; Heart-Assist Devices; Humans; Male; Plat | 2016 |
Dysfunction of a 21-mm aortic bioprosthesis treated with percutaneous implantation of a CoreValve prosthesis.
Topics: Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Calcinosis; Clopidogrel; Combined M | 2013 |
Recurrent episodes of very late stent thrombosis in a patient with aspirin hypersensitivity, stent fracture and malapposition.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Occlusion; Coronary Thrombosis; Drug | 2011 |
Monitoring of acetyl salicylic acid-induced platelet inhibition with impedance aggregometry in children with systemic-to-pulmonary shunts.
Topics: Aspirin; Blalock-Taussig Procedure; Double Outlet Right Ventricle; Electric Impedance; Female; Heart | 2013 |
Early bioprosthetic mitral valve "pseudostenosis" after complete preservation of the native mitral apparatus.
Topics: Aged; Aspirin; Bioprosthesis; Combined Modality Therapy; Coronary Artery Bypass; Drug Therapy, Combi | 2002 |
[False anastomotic iliac (prosthesis-prosthesis) aneurysms: treatment with covered endoprostheses].
Topics: Aneurysm, False; Aneurysm, Ruptured; Anti-Bacterial Agents; Aortic Aneurysm; Aspirin; Blood Vessel P | 2003 |
Clopidogrel plus long-term aspirin after femoro-popliteal stenting. The CLAFS project: 1- and 2-year results.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Anticoagula | 2004 |
Very late thrombosis after implantation of sirolimus eluting stent.
Topics: Adult; Aspirin; Blood Vessel Prosthesis; Catheterization; Clopidogrel; Coronary Angiography; Coronar | 2005 |
Leaflet movement of the ATS valve in the aortic position: unique behavior observed in 19-mm valves.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Sten | 2006 |
Stent thrombosis: consider also low response to antiplatelets.
Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Implants; Humans; Platelet Aggr | 2007 |
Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Clopidogrel; | 2007 |
Acute thrombosis of a prosthetic mitral valve in pregnancy in spite of adjusted-dose low-molecular-weight heparin and aspirin.
Topics: Adult; Aspirin; Dose-Response Relationship, Drug; Echocardiography; Female; Fibrinolytic Agents; Fol | 2008 |
Platelet aggregometry can accurately predict failure of externally supported knitted Dacron femoropopliteal bypass grafts.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Amputation, Surgical; Anastomosis, Surgical; | 1993 |
Successful thrombolysis after prosthetic pulmonary valve obstruction under aspirin monotherapy.
Topics: Adult; Aspirin; Female; Humans; Plasminogen Activators; Platelet Aggregation Inhibitors; Prosthesis | 1997 |
Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiograp | 1998 |
Experience with low-dose aspirin as thromboprophylaxis for the Tissuemed porcine aortic bioprosthesis: a survey of five years' experience.
Topics: Aged; Aged, 80 and over; Aortic Valve; Aspirin; Bioprosthesis; Data Collection; Dose-Response Relati | 1998 |
Synergistic effect of released aspirin/heparin for preventing bovine pericardial calcification.
Topics: Alkaline Phosphatase; Animals; Anticoagulants; Aspirin; Biopolymers; Bioprosthesis; Calcinosis; Calc | 2000 |
The role of an endothelial cell lining in limiting distal anastomotic intimal hyperplasia of 4-mm-I.D. Dacron grafts in a canine model.
Topics: Animals; Aorta, Abdominal; Aspirin; Blood Vessel Prosthesis; Dogs; Endothelium, Vascular; Hyperplasi | 1991 |